 |
BioWorld-International-2007-03-07
Neuropharm Raises £20M To Fund CNS Development Pipeline
Neuropharm Raises £20M To Fund CNS Development Pipeline
LONDON - Neuropharm Group plc raised £20 million (US$38.4 million) in a listing on London's Alternative Investment Market, enabling it to attempt to take Prozac as a treatment for autism through to market and advance the clinical development of three other products for treating pediatric central nervous system disorders. (BioWorld International)